Lentivirus-mediated expression of Drosophila melanogaster deoxyribonucleoside kinase driven by the hTERT promoter combined with gemcitabine: A potential strategy for cancer therapy

International Journal of Molecular Medicine

Volumn 30, Issue 3, 2012, Pages 659-665

  Zhang, Nianqu ^a   Zhao, Lei ^a   Ma, Shuai ^a   Gu, Ming ^a   Zheng, Xinyu ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

Drosophila melanogaster deoxyribonucleoside kinase; hTERT promoter; Lentivirus; Nucleoside analog; Suicide gene

Indexed keywords

DEOXYRIBONUCLEOSIDE; DROSOPHILA MELANOGASTER DEOXYRIBONUCLEOSIDE KINASE; GEMCITABINE; LENTIVIRUS VECTOR; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DROSOPHILA MELANOGASTER; DRUG EFFICACY; FEMALE; FIBROBLAST; FLOW CYTOMETRY; GENE EXPRESSION; GENE TARGETING; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LENTIVIRINAE; MEDIATOR; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TRANSGENICS; TUMOR GROWTH; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; DEOXYCYTIDINE; DROSOPHILA MELANOGASTER; FEMALE; GENE EXPRESSION; GENE ORDER; GENE THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROMOTER REGIONS, GENETIC; TELOMERASE;

EID: 84865191117     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2012.1033     Document Type: Article

References (25)

1. Bertoli A, Franco M, Balzarini J, Johansson M and Karlsson A: Altered deoxyribonucleotide pools in T-lymphoblastoid cells expressing the multisubstrate nucleoside kinase of Drosophila melanogaster. FEBS J 272: 3918-3928, 2005. (Pubitemid 41117223)
2. Knecht W, Mikkelsen NE, Clausen AR, et al: Drosophila melanogaster deoxyribonucleoside kinase activates gemcitabine. Biochem Biophys Res Commun 382: 430-433, 2009.
3. Ma S, Zhao L, Zhu Z, et al: The multisubstrate deoxyribonucleoside kinase of Drosophila melanogaster as a therapeutic suicide gene of breast cancer cells. J Gene Med 13: 305-311, 2011.
4. Zhu Z, Mao L, Zhao L, et al: Synergistic therapeutic effect in gastric cancer cells produced by oncolytic adenovirus encoding Drosophila melanogaster deoxyribonucleoside kinase. Cancer Biol Ther 11: 874-882, 2011.
5. Ito M, Suda Y, Harashima H and Kamiya H: Cytotoxic effect of Drosophila deoxynucleoside kinase gene on replicating plasmid in HeLa cells. Biol Pharm Bull 33: 1223-1227, 2010.
6. Nishino K, Osaki T, Kumagai T, et al: Adenovirus-mediated gene therapy specific for small cell lung cancer cells using a Myc-Max binding motif. Int J Cancer 91: 851-856, 2001. (Pubitemid 32178656)
7. Yu ST, Li C, Lu MH, et al: Noninvasive and real-time monitoring of the therapeutic response of tumors in vivo with an optimized hTERT promoter. Cancer 118: 1884-1893, 2012.
8. Yu B, Zhang Y, Zhan Y, et al: Co-expression of herpes simplex virus thymidine kinase and Escherichia coli nitroreductase by an hTERT-driven adenovirus vector in breast cancer cells results in additive antitumor effects. Oncol Rep 26: 255-264, 2011.
9. Ma S, Qu W, Mao L, et al: Antitumor effects of oncolytic adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase in colorectal cancer. Oncol Rep 27: 1443-1450, 2012.
10. Sandrini MP, Clausen AR, On SL, Aarestrup FM, Munch-Petersen B and Piskur J: Nucleoside analogues are activated by bacterial deoxyribonucleoside kinases in a species-specific manner. J Antimicrob Chemother 60: 510-520, 2007. (Pubitemid 47299864)
11. Anderson LM, Swaminathan S, Zackon I, Tajuddin AK, Thimmapaya B and Weitzman SA: Adenovirus-mediated tissue-targeted expression of the HSVtk gene for the treatment of breast cancer. Gene Ther 6: 854-864, 1999. (Pubitemid 29243660)
12. Tang Q, Zhang D, Wan M and Jin L: Experimental study of the RV-HSV-TK/GCV suicide gene therapy system in gastric cancer. Cancer Biother Radiopharm 22: 755-761, 2007.
13. Pan JG, Zhou X, Luo R and Han RF: The adeno-associated virus-mediated HSV-TK/GCV suicide system: a potential strategy for the treatment of bladder carcinoma. Med Oncol: Oct 20, 2011 (Epub ahead of print).
14. Zheng FQ, Xu Y, Yang RJ, et al: Combination effect of oncolytic adenovirus therapy and herpes simplex virus thymidine kinase/ganciclovir in hepatic carcinoma animal models. Acta Pharmacol Sin 30: 617-627, 2009.
15. Ahn M, Lee SJ, Li X, et al: Enhanced combined tumor-specific oncolysis and suicide gene therapy for prostate cancer using M6 promoter. Cancer Gene Ther 16: 73-82, 2009.
16. Zhang JF, Wei F, Wang HP, et al: Potent antitumor activity of telomerase-dependent and HSV-TK armed oncolytic adenovirus for non-small cell lung cancer in vitro and in vivo. J Exp Clin Cancer Res 29: 52, 2010.
17. Zheng X, Johansson M and Karlsson A: Retroviral transduction of cancer cell lines with the gene encoding Drosophila melanogaster multisubstrate deoxyribonucleoside kinase. J Biol Chem 275: 39125-39129, 2000. (Pubitemid 32058928)
18. Trono D: Lentiviral vectors: turning a deadly foe into a therapeutic agent. Gene Ther 7: 20-23, 2000.
19. Takakura M, Kyo S, Kanaya T, et al: Cloning of human telomerase catalytic subunit (hTERT) gene promoter and identification of proximal core promoter sequences essential for transcriptional activation in immortalized and cancer cells. Cancer Res 59: 551-557, 1999. (Pubitemid 29076049)
20. Cong YS, Wen J and Bacchetti S: The human telomerase catalytic subunit hTERT: organization of the gene and characterization of the promoter. Hum Mol Genet 8: 137-142, 1999. (Pubitemid 29039059)
21. Gu J and Fang B: Telomerase promoter-driven cancer gene therapy. Cancer Biol Ther 2 (Suppl 1): S64-S70, 2003.
22. Knecht W, Sandrini MP, Johansson K, Eklund H, Munch-Petersen B and Piskur J: A few amino acid substitutions can convert deoxyribonucleoside kinase specificity from pyrimidines to purines. EMBO J 21: 1873-1880, 2002. (Pubitemid 34614643)
23. Zhu Z, Ma S, Zhao L, et al: Adenovirus-mediated Drosophila melanogaster deoxyribonucleoside kinase mutants combined with gemcitabine harbor a safe cancer treatment profile. Int J Oncol 38: 745-753, 2011.
24. Zhang C, Wang QT, Liu H, Zhang ZZ and Huang WL: Advancement and prospects of tumor gene therapy. Chin J Cancer 30: 182-188, 2011.
25. Abate-Daga D, Garcia-Rodriguez L, Sumoy L and Fillat C: Cell cycle control pathways act as conditioning factors for TK/GCV sensitivity in pancreatic cancer cells. Biochim Biophys Acta 1803: 1175-1185, 2010.